- Home
- CALM vs NUVL Comparison
CALM vs NUVL Comparison
Compare CALM & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CALM
- NUVL
- Stock Information
- Founded
- CALM 1957
- NUVL 2017
- Country
- CALM United States
- NUVL United States
- Employees
- CALM N/A
- NUVL N/A
- Industry
- CALM Farming/Seeds/Milling
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- CALM Consumer Staples
- NUVL Health Care
- Exchange
- CALM Nasdaq
- NUVL Nasdaq
- Market Cap
- CALM 4.5B
- NUVL 4.9B
- IPO Year
- CALM 1996
- NUVL 2021
- Fundamental
- Price
- CALM $90.76
- NUVL $88.89
- Analyst Decision
- CALM Sell
- NUVL Strong Buy
- Analyst Count
- CALM 3
- NUVL 10
- Target Price
- CALM $66.33
- NUVL $112.60
- AVG Volume (30 Days)
- CALM 459.0K
- NUVL 492.9K
- Earning Date
- CALM 01-02-2025
- NUVL 11-12-2024
- Dividend Yield
- CALM 4.51%
- NUVL N/A
- EPS Growth
- CALM N/A
- NUVL N/A
- EPS
- CALM 8.73
- NUVL N/A
- Revenue
- CALM $2,652,970,000.00
- NUVL N/A
- Revenue This Year
- CALM $12.75
- NUVL N/A
- Revenue Next Year
- CALM N/A
- NUVL N/A
- P/E Ratio
- CALM $10.36
- NUVL N/A
- Revenue Growth
- CALM N/A
- NUVL N/A
- 52 Week Low
- CALM $45.07
- NUVL $56.52
- 52 Week High
- CALM $95.06
- NUVL $113.51
- Technical
- Relative Strength Index (RSI)
- CALM 54.79
- NUVL 38.02
- Support Level
- CALM $90.75
- NUVL $89.62
- Resistance Level
- CALM $93.17
- NUVL $96.24
- Average True Range (ATR)
- CALM 2.14
- NUVL 2.90
- MACD
- CALM -0.40
- NUVL -0.27
- Stochastic Oscillator
- CALM 51.71
- NUVL 15.96
About CALM Cal-Maine Foods Inc.
Cal-Maine Foods Inc produces and sells shell eggs. Its main market is the United States. The company's product portfolio contains nutritionally enhanced, cage-free, organic, and brown eggs. Cal-Maine Foods markets the shell eggs to a diverse group of customers, including grocery-store chains, club stores, and food service distributors. The company's brands are Egg-Land's, Land O' Lakes, Farmhouse, and 4-Grain. The Company has one reportable operating segment, which is the production, grading, packaging, marketing and distribution of shell eggs.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.